A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.

Weijing SunNirmal VeeramachaneniRaed Al-RajabiRashna MadanAnup KasiMazin Al-KasspoolesJoaquina BarandaAnwaar SaeedMilind A PhadnisAndrew K GodwinMojtaba OlyaeeNatalie StreeterAlykhan NagjiJunqiang DaiStephen Williamson

Published in: Cancer medicine (2023)

The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long-time survival benefits.

Keyphrases

phase ii study
locally advanced
rectal cancer
squamous cell carcinoma
cardiac surgery
patients undergoing
advanced non small cell lung cancer
radiation therapy
acute kidney injury
free survival
randomized controlled trial
epidermal growth factor receptor
liver metastases